Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008

Anadys Pharmaceuticals, Inc. announced today that it will present at the 3rd annual BIOCOM Investor Conference on Monday, October 27, 2008 at 11:30 a.m. PDT at the Hyatt Regency La Jolla in San Diego, California. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer. The... 

Tags: Anadys Pharmaceuticals Inc., biopharmaceutical, California, cancer, chronic hepatitis C, hepatitis C, Hyatt Regency La Jolla, San Diego, Securities and Exchange Commission, Steve Worland, treatment of cancer

NASDAQ Administrative Rule Allows a Three Month Extension of Grace Period Related to Minimum Bid Price Compliance

Dynatronics Corporation today announced that under a recently approved administrative rule filed by Nasdaq with the SEC temporarily suspending the $1 minimum bid rule, Dynatronics will now have until approximately March 27, 2009 to comply with this listing requirement. “We are pleased that NASDAQ recognizes the need to make this change in light of the current market environment,” stated... 

Tags: aesthetic products, chiropractic, Dynatronics Corporation, Kelvyn H. Cullimore Jr., physical therapy, plastic surgery, rehabilitation equipment, Securities and Exchange Commission, sports medicine

HealthMarkets’ Subsidiary Introduces New Suite of Dental Insurance Products for Individuals of All Ages

HealthMarkets, Inc. (http://www.healthmarkets.com) announced today that its subsidiary, The MEGA Life and Health Insurance Company, has introduced a new suite of dental insurance products for individuals of all ages in 26 states. HealthMarkets, through its insurance subsidiaries, is a provider of health insurance products for the self-employed, individuals and families and small businesses. “Good... 

Tags: A.M. Best Company, Alabama, Alaska, Arizona, Arkansas, association group, Colorado, Connecticut, dental insurance products, District of Columbia, DLJ Merchant Banking Partners, Georgia, Goldman Sachs Capital Partners, Health Insurance Company, HealthMarkets Inc., Idaho, Indiana, insurance industry, insurance products, insurance subsidiaries, Iowa, Kansas, licensed insurance subsidiaries, Louisiana, Mississippi, Missouri, Nebraska, New Hampshire, New Mexico

S3 Investment Company Announces Release of October 2008 Newsletter

S3 Investment Company, Inc. and its wholly owned Redwood Capital subsidiary, which assists private Chinese companies in accessing the U.S. capital markets through reverse mergers into public companies, today released the October 2008 edition of its investor newsletter, which reviews the recently reported growth of Redwood Capital client Dalian Chuming, which now trades in the U.S. as Energroup Holdings... 

Tags: Acquisition, British Virgin Islands, China, Dalian, direct and indirect subsidiaries, Energroup Holdings Corporation, fresh and prepared pork products, investment banking relationships, Jim Bickel, medical and industrial high-tech products, Nevada, non-stocking distributor, Precious Sheen Investments Limited, Redwood Capital, S3 Investment Company Inc., Securities and Exchange Commission, SINO UJE

Initiation of Clinical Development Builds Upon Broad Potential Shown in Preclinical Studies

Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI – News), an innovative cancer drug discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926, in patients with advanced and/or metastatic solid tumors. IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative of... 

Tags: American Association of Cancer Research, brain cancers, cancer, Cancer Research-National Cancer Institute-European Orga, cancer therapeutics, cancers, Charles M. Rudin, chemo, chemotherapy, drug discovery, Geneva, Infinity Pharmaceuticals Inc., Investment, Johns Hopkins Cancer Center, Julian Adams, medulloblastoma, pharmacokinetics, SCLC, Securities and Exchange Commission, small cell lung cancer, stem cells, Switzerland, treatment of cancer, tumor, tumors, US Food and Drug Administration

Phyhealth Provides Update to Shareholders

Physicians Healthcare Management Group, Inc., a developer of health maintenance organizations (HMOs) in partnership with physicians, today released the following letter to its shareholders: Dear Phyhealth Shareholder: Since our last communication in June 2008, much has happened. I want to update you on the Company’s progress on two of Phyhealth’s 2008 key objectives. First is the Company’s... 

Tags: federal applications, Florida, health insurance coverage, healthcare, healthcare costs, information technologies, Investment, medical malpractice insurance, Medicare, Office of Insurance Regulation, OTC Bulletin Board, Phyhealth Plan Corporation, Physicians Healthcare Management Group Inc., preventive healthcare, Robert L. Trinka, Securities and Exchange Commission

Edwards Lifesciences’ New Transcatheter Heart Valve Data Demonstrate Positive Results

Edwards Lifesciences Corporation, the world leader in the science of heart valves, announced that new data from two studies of the Edwards SAPIEN transcatheter aortic heart valve with the RetroFlex transfemoral delivery system were presented today at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The 30-day... 

Tags: bypass, California, cardiovascular disease, Cardiovascular Research Foundation, Edwards Lifesciences AG, Edwards Lifesciences Corporation, Europe, European Union, investigational device, Irvine, Michael A. Mussallem, open-heart surgery, Securities and Exchange Commission, transcatheter valve technologies, United States Patent and Trademark Office, valve technology, vascular technologies

Boston Scientific Inc. announced comprehensive data from the TAXUS ATLAS clinical program

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, multi-center, single-arm, historically controlled trials, which evaluate the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. The TAXUS Liberte Stent received U.S. Food and Drug Administration approval on Friday. Results... 

Tags: Auckland, Boston Scientific Corporation, Cardiovascular Research Foundation, Center for Cardiac and Vascular Research, DC, Europe, federal law, John A. Ormiston, Mark A. Turco, Mercy Hospital, Michigan, myocardial infarction, New Zealand, patient groups, Securities and Exchange Commission, thrombosis, US Food and Drug Administration, Washington, Washington Adventist Hospital

Similarly Low Rates in Patients With Diabetes Compared to Non-Diabetics

Boston Scientific Corporation (NYSE: BSX – News) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical restenosis in patients... 

Tags: angioplasty, Boston Scientific Corporation, cardiac disease, cardiogenic shock, Cardiovascular Research Foundation, congestive heart failure, DC, diabetes, Donald S. Baim, John M. Lasala, myocardial infarction, renal disease, Securities and Exchange Commission, St. Louis, thrombosis, thrombus, Washington, Washington University School of Medicine

Cell Therapeutics, Inc. announced to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company intends to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which requires a minimum market value of listed securities of $50 million. CTI received a Staff Determination Letter from The NASDAQ Stock Market LLC on October... 

Tags: biopharmaceutical industry, cancer, Cell Therapeutics Inc., NASDAQ 100, oncology products, Seattle, Securities and Exchange Commission, The NASDAQ Stock Market LLC

anadys pharmaceuticals, biocom investor conference, kuwait oil company nurses, kuwait oil company nurse forum, nursing jobs philis